Search

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

EHA-AAH Joint membership

We are pleased to inform that EHA and the Albanian Association of Hematology (AAH) have joined forces and are offering you the possibility of an EHA-AAH Joint Membership in 2023.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

EHA-AHA Joint membership

We are pleased to inform that EHA and the Armenian Hematology Association (AHA) have joined forces and are offering you the possibility of an EHA-AHA Joint Membership in 2023.

Read more

EHA-SRH Joint membership

We are pleased to inform that EHA and the Societatea Română de Hematologie (SRH) have joined forces and are offering you the possibility of an EHA-SRH Joint Membership in 2023.

Read more

EHA-SFH Joint membership

We are pleased to inform that EHA and the Société Française d’Hématologie (SFH) have joined forces and are offering you the possibility of an EHA-SFH Joint Membership in 2024.

Read more